Literature DB >> 3180855

Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.

T Pettersson1, B Fröseth, H Riska, M Klockars.   

Abstract

Hyaluronic acid (HA) was determined with a radiometric assay in the serum and pleural fluid of 85 patients with pleural effusions, including 15 with malignant mesothelioma, 32 with other cancer, 31 with nonmalignant inflammatory diseases, and seven with congestive heart failure. With a cutoff level at 100 mg/L, the pleural fluid concentration of HA was raised in 73 percent of patients (11 of 15) with malignant mesothelioma and in 23 percent with nonmalignant inflammatory diseases, but in none with other cancer and in none with congestive heart failure. The median concentration of pleural fluid HA was significantly higher in patients with mesothelioma than in those with other cancer (p less than 0.005). Determination of carcinoembryonic antigen (CEA) in pleural fluid further helped to differentiate between mesothelioma and other types of cancer; concentrations of CEA above 10 micrograms/L were found in four of 15 (27 percent) patients with mesothelioma, but in 38 percent of the patients with other cancer. We concluded that in the differential diagnosis of pleural effusions associated with malignant tumors a high concentration of HA in pleural fluid combined with a low concentration of CEA suggests malignant mesothelioma as opposed to other types of cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180855     DOI: 10.1378/chest.94.5.1037

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  BTS guidelines for the investigation of a unilateral pleural effusion in adults.

Authors:  N A Maskell; R J A Butland
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Authors:  L Welker; M Müller; O Holz; E Vollmer; H Magnussen; R A Jörres
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

Review 3.  Diagnostic tests in pleural effusion--an update.

Authors:  N Berkman; M R Kramer
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

4.  Hyaluronan synthase expression in pleural malignant mesotheliomas.

Authors:  Naoki Kanomata; Tomoyuki Yokose; Tomoyuki Kamijo; Hiroyuki Yonou; Takahiro Hasebe; Naoki Itano; Koji Kimata; Atsushi Ochiai
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

5.  High and low molecular weight hyaluronic acid differentially influence macrophage activation.

Authors:  Jamie E Rayahin; Jason S Buhrman; Yu Zhang; Timothy J Koh; Richard A Gemeinhart
Journal:  ACS Biomater Sci Eng       Date:  2015-07-13

6.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Authors:  S Tsuji; Y Tsuura; T Morohoshi; T Shinohara; F Oshita; K Yamada; Y Kameda; T Ohtsu; Y Nakamura; Y Miyagi
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 7.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.

Authors:  K Beckenlehner; S Bannke; T Spruss; G Bernhardt; H Schönenberg; W Schiess
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy.

Authors:  M P Rangel; V K de Sá; V Martins; J R M Martins; E R Parra; A Mendes; P C Andrade; R M Reis; A Longatto-Filho; C Z Oliveira; T Takagaki; D M Carraro; H B Nader; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2015-05-08       Impact factor: 2.590

10.  Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas.

Authors:  Maria E Ramos-Nino; Steven R Blumen; Harvey Pass; Brooke T Mossman
Journal:  Mol Cancer       Date:  2007-12-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.